Neurocrine Biosciences (NBIX) – Research Analysts’ Weekly Ratings Updates

Several analysts have recently updated their ratings and price targets for Neurocrine Biosciences (NASDAQ: NBIX):

• 11/7/2026 – Neurocrine Biosciences was upgraded by Wall Street Zen from “hold” to “buy”.
• 11/4/2026 – Neurocrine Biosciences had its price target raised by Guggenheim from $207.00 to $224.00. They now have a “buy” rating on the stock.
• 11/3/2026 – Neurocrine Biosciences had its price target raised by Morgan Stanley from $183.00 to $185.00. They now have an “equal weight” rating on the stock.
• 11/3/2026 – Neurocrine Biosciences had its price target raised by Royal Bank Of Canada from $187.00 to $190.00. They now have an “outperform” rating on the stock.
• 11/3/2026 – Neurocrine Biosciences had its price target raised by Canaccord Genuity Group from $210.00 to $220.00. They now have a “buy” rating on the stock.
• 11/3/2026 – Neurocrine Biosciences had its price target raised by Piper Sandler from $210.00 to $215.00. They now have an “overweight” rating on the stock.
• 10/16/2026 – Neurocrine Biosciences had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $204.00 price target on the stock.
• 10/14/2026 – Neurocrine Biosciences was upgraded by Weiss Ratings from “hold (c+)” to “buy (b-)”.
• 10/12/2026 – Neurocrine Biosciences had its price target lowered by BMO Capital Markets from $164.00 to $150.00. They now have a “market perform” rating on the stock.
• 10/6/2026 – Neurocrine Biosciences is now covered by Guggenheim. They set a “buy” rating and a $207.00 price target on the stock.
• 9/29/2026 – Neurocrine Biosciences was downgraded by Weiss Ratings from “buy (b-)” to “hold (c+)”.
• 9/29/2026 – Neurocrine Biosciences had its price target lowered by UBS Group from $231.00 to $214.00. They now have a “buy” rating on the stock.
• 9/16/2026 – Neurocrine Biosciences was upgraded by Mizuho to “hold”.
• 9/11/2026 – Neurocrine Biosciences had its price target raised by Morgan Stanley from $182.00 to $183.00. They now have an “equal weight” rating on the stock.

Neurocrine Biosciences Stock Up 0.2%

Shares of NBIX stock traded up $0.28 on Tuesday, reaching $169.14. The stock had a trading volume of 1,058,497 shares, compared to its average volume of 1,242,465. Neurocrine Biosciences, Inc. has a 12 month low of $122.14 and a 12 month high of $186.12. The firm has a market capitalization of $17.12 billion, a price-to-earnings ratio of 25.09, a P/E/G ratio of 0.74 and a beta of 0.36. The firm’s 50-day moving average is $147.51 and its two-hundred day moving average is $148.22.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings results on Monday, November 2nd. The company reported $3.29 EPS for the quarter, topping analysts’ consensus estimates of $1.91 by $1.38. The business had revenue of $1.12 billion during the quarter, compared to analysts’ expectations of $1.04 billion. Neurocrine Biosciences had a return on equity of 23.39% and a net margin of 18.98%. Neurocrine Biosciences’s quarterly revenue was up 41.3% on a year-over-year basis. During the same quarter last year, the company posted $2.04 earnings per share. On average, sell-side analysts forecast that Neurocrine Biosciences, Inc. will post 8.41 earnings per share for the current fiscal year.

Insider Activity

In related news, insider David W. Boyer sold 826 shares of the business’s stock in a transaction that occurred on Monday, September 14th. The stock was sold at an average price of $157.45, for a total transaction of $130,053.70. Following the transaction, the insider directly owned 8,722 shares of the company’s stock, valued at approximately $1,373,278.90. The trade was a 8.65% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director George Morrow sold 7,200 shares of the stock in a transaction on Tuesday, November 3rd. The shares were sold at an average price of $166.37, for a total value of $1,197,864.00. Following the completion of the sale, the director owned 10,386 shares in the company, valued at approximately $1,727,918.82. This trade represents a 40.94% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 18,137 shares of company stock valued at $2,829,332 over the last three months. Insiders own 4.60% of the company’s stock.

Neurocrine Biosciences is a biopharmaceutical company focused on developing and commercializing treatments for neurological, endocrine and related disorders. Founded in 1992 and headquartered in San Diego, California, the company conducts research and development alongside its commercial operations. Its marketed medicines include INGREZZA (valbenazine), approved in the United States for tardive dyskinesia and chorea associated with Huntington disease, and CRENESSITY (crinecerfont), used with glucocorticoid replacement therapy to treat classic congenital adrenal hyperplasia in adults and children.